Biological Products, (No Diagnostic Substances)
BIO-TECHNE Corp (TECH) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 56/100 — a percentile rank of BIO-TECHNE Corp’s fundamentals against Manufacturing peers.
Is BIO-TECHNE Corp overvalued? P/E looks fair vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.
Consensus: Hold from 26 analysts (Buy 12 · Hold 14).
Average price target: $71.67 (−1.4% vs $72.71); range $65–$73.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 0 · Open-market sells: 0 · Net: +$0
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!